Helix BioPharma Terminates GEM Financing Facility After Strategic Review
TL;DR
Helix BioPharma cancels GEM financing to protect shareholder value and seek better capital alignment for advancing its oncology pipeline.
Helix terminated the GEM equity facility after market evaluation, with shareholder approval obtained but binding agreements not executed due to strategic misalignment.
Helix prioritizes long-term value to sustain cancer research, ensuring resources advance treatments for hard-to-treat cancers and improve patient outcomes.
Helix BioPharma, an oncology innovator, abandons a major financing deal to explore better options for its clinical programs.
Found this article helpful?
Share it with your network and spread the knowledge!
Helix BioPharma Corp. has elected not to proceed with a previously announced equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited. The company entered into a non-binding term sheet with GEM on October 15, 2024, and had received shareholder approval for the financing arrangement at its annual general and special meeting on March 26, 2025. Following a thorough evaluation of market conditions and long-term corporate objectives, Helix determined that the GEM facility no longer aligns with its capital strategy or its commitment to maximizing long-term shareholder value. The letter of intent expired according to its terms, and the company has chosen not to execute binding agreements or pursue the financing with GEM.
This decision represents a significant strategic shift for the biopharmaceutical company, which had previously secured shareholder endorsement for the financing arrangement. The proposed subscription facility had been disclosed in multiple company announcements, including news releases dated February 24, 2025 and March 26, 2025, as well as in the company's Management and Information Circular dated January 31, 2025. Additional details about the company's activities and meeting results can be found through its corporate communications at https://www.helixbiopharma.com/fy2025/helix-biopharma-corp-extends-date-of-annual-general-and-special-meeting-to-seek-approval-of-asset-acquisitions-and-proposed-financing/ and https://www.helixbiopharma.com/fy2025/helix-biopharma-corp-announces-voting-results-from-its-annual-general-and-special-meeting/.
Independently of this decision, Helix continues to engage in constructive discussions with financial partners to explore alternative financing structures that may better align with the company's needs and strategic direction. The company remains committed to securing the capital required to advance its clinical programs and achieve its corporate objectives. This strategic pivot underscores the company's focus on maintaining financial flexibility while pursuing growth opportunities that support sustainable long-term value creation for shareholders. The termination of the GEM facility reflects a calculated response to evolving market conditions and represents the company's commitment to prudent capital management in the dynamic biopharmaceutical sector.
Curated from NewMediaWire
